News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
112,395 Results
Type
Article (17130)
Company Profile (30)
Press Release (95228)
Multimedia
Podcasts (193)
Webinars (22)
Section
Business (31756)
Career Advice (1019)
Deals (5946)
Drug Delivery (97)
Drug Development (13653)
Employer Resources (156)
FDA (2830)
Job Trends (3916)
News (54056)
Policy (5113)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Standard (1)
Academia (668)
Academic (1)
Accelerated approval (14)
Adcomms (11)
Allergies (25)
Alliances (8043)
ALS (39)
Alzheimer's disease (441)
Antibody-drug conjugate (ADC) (107)
Approvals (2750)
Artificial intelligence (222)
Autoimmune disease (47)
Automation (8)
Bankruptcy (65)
Best Places to Work (2058)
BIOSECURE Act (12)
Biosimilars (75)
Biotechnology (17)
Bladder cancer (70)
Brain cancer (25)
Breast cancer (136)
Cancer (1147)
Cardiovascular disease (145)
Career advice (894)
Career pathing (36)
CAR-T (85)
CDC (29)
Celiac Disease (1)
Cell therapy (240)
Cervical cancer (9)
Clinical research (11010)
Collaboration (473)
Company closure (1)
Compensation (68)
Complete response letters (23)
COVID-19 (689)
CRISPR (23)
C-suite (283)
Cystic fibrosis (41)
Data (1179)
Decentralized trials (2)
Denatured (73)
Depression (52)
Diabetes (130)
Diagnostics (1172)
Digital health (13)
Diversity (10)
Diversity, equity & inclusion (42)
Drug discovery (110)
Drug pricing (94)
Drug shortages (24)
Duchenne muscular dystrophy (82)
Earnings (8394)
Editorial (47)
Employer branding (22)
Employer resources (132)
Events (13237)
Executive appointments (314)
FDA (3387)
Friedreich's ataxia (4)
Frontotemporal dementia (3)
Funding (403)
Gene editing (64)
Generative AI (29)
Gene therapy (241)
GLP-1 (478)
Government (1141)
Grass and pollen (2)
Guidances (71)
Healthcare (3341)
HIV (12)
Huntington's disease (19)
IgA nephropathy (27)
Immunology and inflammation (116)
Immuno-oncology (20)
Indications (31)
Infectious disease (765)
Inflammatory bowel disease (44)
Inflation Reduction Act (11)
Influenza (13)
Intellectual property (38)
Interviews (157)
IPO (1818)
IRA (31)
Job creations (1767)
Job search strategy (748)
JPM (63)
Kidney cancer (2)
Labor market (89)
Layoffs (306)
Leadership (24)
Legal (1122)
Liver cancer (21)
Longevity (10)
Lung cancer (200)
Lymphoma (58)
Machine learning (23)
Management (44)
Manufacturing (297)
MASH (43)
Medical device (2210)
Medtech (2218)
Mergers & acquisitions (4350)
Metabolic disorders (507)
Multiple sclerosis (30)
NASH (11)
Neurodegenerative disease (109)
Neuropsychiatric disorders (43)
Neuroscience (780)
Neurotech (1)
NextGen: Class of 2026 (1672)
Non-profit (881)
Now hiring (59)
Obesity (309)
Opinion (170)
Ovarian cancer (15)
Pain (43)
Pancreatic cancer (40)
Parkinson's disease (59)
Partnered (25)
Patents (98)
Patient recruitment (83)
Peanut (8)
People (11489)
Pharmaceutical (6)
Pharmacy benefit managers (7)
Phase 1 (3033)
Phase 2 (4537)
Phase 3 (4851)
Pipeline (1103)
Policy (194)
Postmarket research (346)
Preclinical (1275)
Press Release (33)
Prostate cancer (66)
Psychedelics (41)
Radiopharmaceuticals (90)
Rare diseases (325)
Real estate (2604)
Recruiting (59)
Regulatory (3859)
Reports (54)
Research institute (621)
Resumes & cover letters (165)
Rett syndrome (4)
RNA editing (11)
RSV (21)
Schizophrenia (47)
Series A (94)
Series B (49)
Service/supplier (3)
Sickle cell disease (28)
Special edition (27)
Spinal muscular atrophy (35)
Sponsored (26)
Startups (1129)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (37)
The Weekly (118)
Vaccines (359)
Venture capital (70)
Weight loss (251)
Women's health (37)
Worklife (20)
Date
Today (29)
Last 7 days (127)
Last 30 days (507)
Last 365 days (6023)
2026 (724)
2025 (6083)
2024 (6884)
2023 (7091)
2022 (11235)
2021 (11705)
2020 (9937)
2019 (8573)
2018 (6287)
2017 (6275)
2016 (5972)
2015 (6751)
2014 (4389)
2013 (2714)
2012 (2730)
2011 (3079)
2010 (2395)
Location
Africa (352)
Alabama (12)
Arizona (30)
Arkansas (1)
Asia (5997)
Australia (1048)
California (1737)
Canada (396)
China (221)
Colorado (66)
Connecticut (75)
Delaware (62)
Europe (19183)
Florida (318)
Georgia (88)
Idaho (11)
Illinois (193)
India (23)
Indiana (108)
Iowa (9)
Japan (72)
Kansas (18)
Kentucky (5)
Louisiana (4)
Maine (3)
Maryland (168)
Massachusetts (1391)
Michigan (81)
Minnesota (94)
Mississippi (2)
Missouri (15)
Montana (7)
Nebraska (9)
Nevada (23)
New Hampshire (13)
New Jersey (613)
New Mexico (11)
New York (461)
North Carolina (250)
North Dakota (2)
Northern California (857)
Ohio (44)
Oklahoma (4)
Oregon (23)
Pennsylvania (348)
Puerto Rico (3)
Rhode Island (11)
South America (413)
South Carolina (12)
South Dakota (1)
Southern California (664)
Tennessee (27)
Texas (271)
United States (6509)
Utah (55)
Virginia (56)
Washington D.C. (16)
Washington State (114)
West Virginia (3)
Wisconsin (28)
112,395 Results for "chiesi farmaceutici spa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
February 1, 2026
·
13 min read
Press Releases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
February 1, 2026
·
9 min read
Deals
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. announced the completion of the acquisition of Amryt Pharma Plc, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases.
April 12, 2023
·
3 min read
Deals
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. and Amryt Pharma Plc announced that the companies have entered into a definitive agreement under which Chiesi will acquire Amryt.
January 8, 2023
·
12 min read
Press Releases
Chiesi Global Rare Diseases Reinforces Long-Term Commitment to the Rare Disease Community with Multiple Abstract Presentations at the 22nd Annual WORLDSymposium™
February 5, 2026
·
7 min read
Business
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
Gossamer Bio, Inc. and Chiesi Farmaceutici S.p.A announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.
May 6, 2024
·
9 min read
Press Releases
Chiesi Announces FDA Acceptance of New Drug Application for its Triple Combination Inhaler for the Maintenance Treatment of Asthma
October 16, 2025
·
6 min read
Press Releases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
November 3, 2025
·
9 min read
Press Releases
Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU
October 20, 2025
·
11 min read
Business
Nemysis Limited Announces a Strategic Alliance With Bruno Farmaceutici S.p.A.
Nemysis is pleased to announce that it has entered into a Strategic Alliance Agreement with Bruno Farmaceutici S.p.A. for the mutual advancement of the portfolio and sales of each company.
November 8, 2023
·
2 min read
1 of 11,240
Next
